ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.701,96
-0,35%
S&P 500
5.308,13
0,09%
Dow Jones
39.806,77
-0,49%
Euro vs US Dollar
1,08671
0,06%
Bitcoin
71.029,30
-0,59%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) News

BCRX BioCryst Pharmaceuticals Inc

6,13
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:52:29
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
BioCryst Pharmaceuticals Inc BCRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 6,13 10:52:29
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
6,13
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
15.5.202413:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.5.202413:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.5.202413:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.5.202413:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.5.202413:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.5.202413:00GLOBEBioCryst to Present New Data at 2024 Meeting of the European..
13.5.202413:00GLOBEORLADEYO® (berotralstat) Approved in Mexico
09.5.202413:00GLOBEBioCryst Presents New Real-world Evidence Showing..
07.5.202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.5.202413:00GLOBEBioCryst to Present at Upcoming Investor Conferences
06.5.202413:03EDGAR2Form 8-K - Current report
06.5.202413:00GLOBEBioCryst Reports First Quarter 2024 Financial Results and..
03.5.202413:00GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
22.4.202413:00GLOBEBioCryst to Report First Quarter 2024 Financial Results on..
17.4.202410:30GLOBEBioCryst Announces Approval of ORLADEYO® (berotralstat) by..
03.4.202413:00GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
25.3.202421:01GLOBEBioCryst to Present at Upcoming Investor Conferences
05.3.202413:01GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
04.3.202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202423:05EDGAR2Form S-3ASR - Automatic shelf registration statement of..
26.2.202413:05EDGAR2Form 8-K - Current report
26.2.202413:00GLOBEBioCryst Reports Fourth Quarter and Full Year 2023 Financial..
26.2.202411:57IHMARKETNEWSU.S. Index Futures Dip Amid Inflation Data Anticipation, Oil..
23.2.202413:00GLOBEBioCryst Presents New Real-world Data Showing Rapid,..
21.2.202422:01GLOBEBioCryst to Present at Upcoming Investor Conferences
19.2.202413:54GLOBEBioCryst Launches ORLADEYO® (berotralstat) in Italy
14.2.202422:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202415:02EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12.2.202413:00GLOBEBioCryst to Report Fourth Quarter 2023 Financial Results on..
05.2.202413:00GLOBEBioCryst to Present New ORLADEYO® (berotralstat) Real-world..
02.2.202413:00GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
24.1.202423:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18.1.202423:21EDGAR2Form 8-K - Current report
08.1.202413:02EDGAR2Form 8-K - Current report
05.1.202422:01GLOBEBioCryst Announces Preliminary Full Year 2023 ORLADEYO®..
04.1.202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:01GLOBEBioCryst Reports Inducement Grants Under Nasdaq Listing Rule..
03.1.202413:00GLOBEBioCryst to Present at 42nd Annual J.P. Morgan Healthcare..
20.12.202322:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.12.202313:00GLOBEBioCryst Announces Publication of Data from Open-label..
18.12.202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.12.202322:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.12.202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.12.202322:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.12.202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

NASDAQ
BCRX
BioCryst Pharmaceuticals
LSE
TCHN
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten